



1624
Few

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Braj Bhushan Lohray, et al

Serial No.: 10/007,109

Group No. 1624

Filed: November 19, 2001

Examiner: Kifle, Bruck

For: NOVEL TRICYCLIC COMPOUNDS AND THEIR USE IN MEDICINE, PROCESS
FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS
CONTAINING THEM

Attorney Docket No.: U 013701-9

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

We draw the attention of the Examiner to the references listed on the attached Form PTO-1449. Copies of the references are not required, because they were already filed in a U.S. application from which an earlier filing date is claimed in this application.

CERTIFICATION UNDER 37 C.F.R. 1.8(a) and 1.10*
(When using Express Mail, the Express Mail label number is **mandatory**;
Express Mail certification is optional.)

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. 1.8(a)

with sufficient postage as first class mail.

37 C.F.R. 1.10*

as "Express Mail Post Office to Addressee"
Mailing Label No. _____ (mandatory)

TRANSMISSION

transmitted by facsimile to the Patent and Trademark Office, to (703) 872-9306

Signature

Janet I. Cord

(type or print name of person certifying)

Date: September 15, 2004

*WARNING: Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. 1.10(b).

"Since the filing of correspondence under § 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

09/17/2004 SDIRETA1 00000103 10007109
01 FC:1806 180.00 OP

(Information Disclosure Statement Short Form—page 1 of 1) 6-1a

Respectfully submitted,



JANET I. CORD
c/o LADAS & PARRY, LLP
26 WEST 61st STREET
NEW YORK, NEW YORK 10023
REG. NO. 33,778 (212) 708-1935



practitioner's Docket No. U 013701-9

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: **Braj Bhushan Lohray, et al.**

Application No.: **10/007,109**

Filed: **November 19, 2001**

For: **NOVEL TRICYCLIC COMPOUNDS AND THEIR USE IN MEDICINE, PROCESS FOR
THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM**

Group No.: **1624**

Examiner: **N/A**

Commissioner for Patents

P. O. Box 1450

Alexandria, VA 22313-1450

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
BEFORE MAILING DATE OF EITHER A FINAL ACTION
OR NOTICE OF ALLOWANCE (37 C.F.R. 1.97(c))**

NOTE: 37 C.F.R. 1.97: "(c) An information disclosure statement shall be considered by the Office if filed after the period specified in paragraph (b) of this section, provided that the information disclosure statement is filed before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311, or an action that otherwise closes prosecution in the application, and it is accompanied by one of:

- (1) The statement specified in paragraph (e) of this section; or
- (2) The fee set forth in § 1.17(p)."

NOTE: "If a final action or notice of allowance is mailed in an application and later withdrawn, the application will be considered as not having had a final action or notice of allowance mailed for purposes of considering an information disclosure statement." Notice of April 20, 1992 (1138 O.G. 37-41, 39).

CERTIFICATION UNDER 37 C.F.R. 1.8(a) and 1.10*

*(When using Express Mail, the Express Mail label number is mandatory;
Express Mail certification is optional.)*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents , P. O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. 1.8(a)

37 C.F.R. 1.10* (Preferred)

with sufficient postage as first class mail.

as "Express Mail Post Office to Address"
Mailing Label No. _____ (mandatory)

TRANSMISSION

transmitted by facsimile to the Patent and Trademark Office, to (703) 872-9306

Signature

Janet I. Cord

(type or print name of person certifying)

* Only the date of filing (§ 1.6) will be the date used in a patent term adjustment calculation, although the date on any certificate of mailing or transmission under § 1.8 continues to be taken into account in determining timeliness. See § 1.703(f). Consider "Express Mail Post Office to Addressee" (§ 1.10) or facsimile transmission (§ 1.6(d)) for the reply to be accorded the earliest possible filing date for patent term adjustment calculations.

NOTE: 37 C.F.R. § 1.704(d): "A paper containing only an information disclosure statement in compliance with §§ 1.97 and 1.98 will not be considered a failure to engage in reasonable efforts to conclude prosecution (processing or examination) of the application under paragraphs (c)(6), (c)(8), (c)(9), or (c)(10) of this section if it is accompanied by a statement that each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the information disclosure statement. This thirty-day period is not extendable."

NOTE: "If information submitted during the period set forth in 37 C.F.R. 1.97(c) with a certification is used in a new ground of rejection on unamended claims, the next Office action will not be made final since in this situation it is clear that applicant has submitted the information to the office promptly after it has become known and the information is being submitted prior to a final determination on patentability by the Office. However, the information submitted with a certification can be used in a new ground of rejection and the next Office action made final, [i]f the new ground of rejection was necessitated by amendment of the application by applicant. Where the information is submitted during this period with a fee, the examiner may use the information submitted, e.g., printed publication or evidence of public use, and make the next Office action final whether or not the claims have been amended, provided that no other new ground of rejection which was not necessitated by amendment to the claims is introduced by the examiner. See MPEP 706.07(a). If a new ground of rejection is introduced that is neither necessitated by an amendment to the claims nor based on the information submitted with the fee set forth in 37 C.F.R. 1.17(p), the Office action shall not be made final. Notice of April 20, 1992 (1138 O.G. 37-41, 39).

WARNING: "A petition for suspension of action to allow applicant time to submit an information disclosure statement will be denied as failing to present good and sufficient reasons, since 37 C.F.R. 1.97 provides adequate recourse for the timely submission of prior art for consideration by the examiner." Notice of July 6, 1992 (1141 O.G. 63). But see § 103(b) and (c), limited suspension of action in a continued prosecution application (CPA) filed under § 1.53(d) and in a request for continued examination (RCE) under § 1.114.

WARNING: No extension of time can be had under 37 C.F.R. 1.136(a) or (b) for filing an IDS. 37 C.F.R. 1.97(f).

TIME OF TRANSMITTAL OF ACCOMPANYING INFORMATION DISCLOSURE STATEMENT

1. The information disclosure statement transmitted herewith is being filed *after* three months of the filing date of this national application or the date of entry of the national stage as set forth in § 1.491 in an international application or after the mailing date of the first Office action on the merits, whichever event occurred last but *before* the mailing date of either:

- (1) a final action under § 1.113 or
- (2) a notice of allowance under § 1.311,

whichever occurs first.

STATEMENT OR FEE

2. Accompanying this transmittal is
(check either A or B below)

A. a statement as specified in 37 C.F.R. 1.97(e).

OR


B. the fee set forth in 37 C.F.R. 1.17(p) for submission of an information disclosure statement under § 1.97(c). (\$180.00).

METHOD OF PAYMENT OF FEE

3. Attached is a check in the amount of \$ 180.00.

[] Charge Account No. _____ in the amount of \$ _____.
A duplicate of this request is attached.

If any additional fees are due, please charge Account 12-0425.


SIGNATURE OF PRACTITIONER

Reg. No. 33,778

Janet I. Cord

(type or print name of practitioner)

Tel. No.: (212) 708-1935

P.O. Address

Customer No.: 01400

c/o Ladas & Parry LLP
26 West 61st Street
New York, N.Y. 10023

FORM PTO-1449

U. S DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	SERIAL NO.
U 013701-9	10/007,109
APPLICANT	
Braj Bhushan LOHRAY, et al	
FILING DATE	GROUP
November 19, 2001	1624



REFERENCE DESIGNATION		U.S. PATENT DOCUMENTS			FILING DATE IF APPROPRIATE
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME		
AA	5,593,970	01/1997	Attardo, et al.		
AB					
AC					
AD					
AE					
AF					
AG					
AH					
AI					
AJ					

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AK	0903343	03/1999	EP		
	AL	00/26200	05/2000	WO		
	AM	0916651	05/1999	EP		
	AN	1026149	08/2000	EP		
	AO					
	AP					

OTHER ART (Including Author, Title, Date, Pertinent Dates, Etc.)

AQ	CAS abstract AN 1994: 482641 of Tetrahedron Letters (1994), 35(19), 3139-42 in particular compounds RN 156335-15-9, RN 156335-16-9, RN 156335-21-6
AR	CAS abstract AN 1979: 438972 of Chemische Berichte (1979), 112(5), 1571-84 in particular compound RN 70680-30-7
AS	CAS abstract AN 1972: 526535 of Tetrahedron Letters (1972), (29), 2911-14 in particular compound RN 38291-54-2

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.